Federal prosecutors say McMillan used Protectus LLC and five related Nevada entities to support an alleged skin-substitute operation that continued from May 2019 through at least February 2026
WASHINGTON, DC — Federal prosecutors have placed Protectus LLC at the organizational center of a sweeping healthcare fraud indictment, alleging that Michael McMillan used the company and several related entities to recruit providers, distribute skin substitutes, support billing, collect reimbursements, and pay commissions.
The nine-count case describes an operation that allegedly continued for nearly seven years, reached medical practices across several states, and converted approximately $268 million in payments from Medicare, TRICARE, and CHAMPVA into provider margins, corporate receipts, sales compensation, and valuable personal property.
McMillan, a 55-year-old resident of Las Vegas, is the only defendant named in the indictment, while Protectus LLC and the related companies are described as businesses he owned and controlled rather than separately charged corporate defendants.
Every accusation remains unproven, McMillan retains the presumption of innocence, and neither control of several companies nor a corporate name on an invoice establishes criminal responsibility without admissible evidence satisfying every statutory element beyond a reasonable doubt.
Six Companies Under the Protectus Name
According to the federal indictment against Michael McMillan, prosecutors collectively use the name Protectus for six Nevada limited liability companies: Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC.
That collective definition matters because the charging document does not describe Protectus as merely one storefront, one bank account, or one isolated distributor, but as an interconnected group allegedly owned and directed by the same individual.
The indictment repeatedly attributes operational conduct to “McMillan and Protectus,” a formulation encompassing product supply, provider recruitment, billing assistance, percentage-based invoicing, representative compensation, reimbursement tracking, and the receipt of approximately $174 million from the challenged arrangements.
Prosecutors do not provide a complete corporate history for each entity, identify every employee, or assign every alleged act to one particular company, leaving entity-specific roles, capitalization, contracts, staffing, and financial boundaries likely subjects for discovery and defense scrutiny.
Protectus LLC is therefore central to the government’s narrative, but the word “vehicle” should be understood as an allegation that corporate infrastructure facilitated the challenged transactions, not as a judicial finding that any company existed solely for an unlawful purpose.
The Alleged Corporate Operating System
Federal investigators portray the Protectus companies as an operating system connecting skin-substitute inventory with provider recruitment, clinical applications, government claims, insurer adjudication, company invoices, provider profits, recruiter commissions, bank deposits, and later purchases of real estate, vehicles, and an aircraft.
In that narrative, the entities allegedly did more than sell wound-care products at a fixed wholesale price, because employees also monitored claim outcomes, helped practices prepare billing, supplied pricing information, calculated reimbursement shares, processed refunds, and prepared monthly commission reports.
The government’s theory depends upon those functions operating together, since no-upfront-cost inventory allegedly attracted providers, billing assistance helped generate claims, contingent invoices divided successful reimbursements, and percentage commissions encouraged representatives to recruit additional practices into the same structure.
A legitimate medical distributor may lawfully perform many comparable administrative tasks, including offering credit, providing coding education, tracking accounts receivable, and compensating sales personnel, which means prosecutors must prove that Protectus performed its functions with fraudulent and kickback-related intent.
The corporate-vehicle allegation will therefore turn on economic substance rather than organizational appearance, asking whether the six entities supported genuine product distribution on compliant terms or knowingly enabled remuneration and false pricing representations tied to federally reimbursed orders.
A Timeline Extending From 2019 Into 2026
The indictment places the alleged conspiracies beginning in or around May 2019 and says the conduct continued through at least February 2026, creating a period long enough for prosecutors to examine recurring business practices rather than a single disputed invoice.
That chronology crosses major changes in the wound-care marketplace, government payment policies, product availability, provider participation, and enforcement attention, making dated contracts, price sheets, guidance, emails, personnel assignments, and billing instructions especially important when evaluating knowledge over time.
Prosecutors allege that McMillan acted through his companies and with unnamed co-conspirators throughout that period, while recruiting physicians, podiatrists, nurse practitioners, and other providers in Texas, California, Utah, and potentially additional jurisdictions not identified publicly.
The indictment specifically describes five providers and four sales representatives through anonymous letter designations, a common charging approach that protects identities while still outlining how North Texas participants allegedly connected a Nevada-controlled company network with federal healthcare payments.
For the defense, the extended timeline can create opportunities to show policy changes, different employee responsibilities, separate contracts, lawful advice, evolving product lines, or periods without misconduct, rather than treating every transaction across nearly seven years identically.
For prosecutors, the same duration can help show repetition, standardized percentages, ongoing approval, and institutional knowledge, particularly if contemporaneous records show comparable invoice and commission procedures across providers, states, products, employees, and corporate accounts.
How Protectus Allegedly Removed Provider Risk
The indictment says Protectus supplied skin-substitute products without requiring medical providers to pay upfront, permitting practices to apply expensive products and seek government reimbursement before incurring the acquisition obligation ordinarily associated with delivered medical inventory.
If Medicare or another government program denied a claim, Protectus allegedly did not charge the provider for that product, shifting denial risk away from the practice and making participation financially safer than a conventional purchase that requires payment regardless of insurer adjudication.
When a claim succeeded, prosecutors say the companies charged approximately 60 percent to 70 percent of the reimbursement, allowing the provider to retain approximately 30 percent to 40 percent and potentially earn thousands of dollars from each paid product claim.
The government characterizes that retained amount as an illegal kickback disguised as a rebate or discount, while McMillan may argue that the arrangement represented lawful net pricing, commercial credit, risk allocation, or a documented concession within a volatile reimbursement environment.
Protectus’s alleged role as the corporate vehicle becomes clearest at that point, because the companies purportedly controlled product delivery, claim assistance, reimbursement confirmation, invoice timing, percentage calculations, collections, and representative payments within one coordinated commercial cycle.
Invoices Identified Particular Protectus Entities
An October 2022 QuickBooks invoice allegedly sent to a Utah podiatrist identified Protectus Technologies LLC as the company owed $37,537 after the provider collected $53,625 and retained $16,087, producing the 70-to-30-percent division described by prosecutors.
That invoice matters beyond its arithmetic because it places one specific company within a provider transaction, potentially allowing investigators to connect corporate books, tax records, banking activity, employee access, product shipments, and authorization procedures with the alleged reimbursement-sharing arrangement.
In July 2023, Protectus LLC allegedly sent an Arlington physician another invoice exceeding $82,000, after which a practice employee complained that the calculation showed a 35-percent provider profit despite a newer contract promising 40 percent.
McMillan allegedly forwarded that complaint to a Protectus employee with instructions to correct it, an exchange prosecutors may use to argue that he personally supervised the percentage retained by a recruited provider under the companies’ reimbursement-based system.
The practice later paid more than $76,000 to Protectus, and a representative’s subsequent commission allegedly included money derived partly from that invoice, providing investigators with a documentary sequence from provider reimbursement through corporate collection and recruiter compensation.
The defense can seek the complete invoices, underlying contracts, amendments, purchase orders, credits, refunds, claim records, and accounting ledgers, because selected descriptions may not reveal every enforceable obligation or commercial reason supporting the numbers shown.
QuickBooks, Emails, and Commission Reports
The indictment’s corporate narrative relies heavily upon routine business records, including QuickBooks invoices, reimbursement reports, emails, text messages, checks, spreadsheets, commission calculations, explanations of benefits, and bank transfers that allegedly documented how money moved through Protectus.
Such records can be powerful because they were generally created during ordinary operations rather than after an investigation began, although their meaning remains contestable when terminology, accounting conventions, incomplete threads, employee assumptions, or missing attachments create ambiguity.
One representative allegedly questioned why a commission report omitted more than $6,400, and a Protectus employee responded that commissions could be paid only after the office reported receiving an insurance payment on the underlying claim.
Another monthly report allegedly documented a payment exceeding $120,000 to a Utah representative, including compensation tied to the profits Protectus generated from the provider invoice, and the division of more than $53,000 in collected reimbursement.
Those records support the government’s assertion that representative compensation depended upon successful healthcare payments rather than simply product delivery, while the defense may argue that lawful sales commissions commonly become payable only after customers actually pay outstanding invoices.
The critical distinction will involve purpose, statutory coverage, transaction structure, and knowledge, because contingency alone does not automatically prove criminality, while compensation intended to induce federally reimbursable purchasing decisions can create serious Anti-Kickback Statute exposure.
The Company’s Alleged Role in Claims Billing
Prosecutors say McMillan and Protectus employees either billed on behalf of medical providers or helped those providers submit claims, positioning the companies close to the pricing information presented to Medicare, TRICARE, and CHAMPVA for payment.
The indictment alleges that certain claims reported an inflated acquisition price instead of the provider’s actual cost after discounts, rebates, refunds, and other adjustments, with the disputed information appearing in Box 19 of Medicare claim submissions.
That allegation links corporate operations directly with the healthcare fraud count, because the government contends Protectus did not merely receive money after an independent provider submission but participated in preparing or influencing materially inaccurate pricing information.
In May 2024, a Protectus employee allegedly told a Texas podiatrist that a paid claim missing Box 19 information required resubmission using information from a company spreadsheet, after Medicare paid one related claim and denied another.
Protectus then allegedly issued an invoice for $5,865, exactly 65 percent of the $9,024 payment the provider had reported, while the denied product generated no comparable immediate charge under the arrangement described in the indictment.
McMillan’s attorneys can examine which entity employed the billing personnel, who prepared the spreadsheet, what government instructions applied, whether providers controlled final submissions, and whether outside experts or compliance professionals approved the challenged methodology.
Prosecutors must establish material falsity and criminal intent through more than corporate proximity, since a distributor’s administrative involvement, an employee’s coding mistake, or a reasonable interpretation of complicated billing guidance does not necessarily prove a knowing fraud conspiracy.
Three Government Programs Allegedly Paid the Claims
Medicare, TRICARE, and CHAMPVA allegedly paid approximately $268 million for skin-substitute claims associated with the challenged operation, bringing elderly or disabled beneficiaries, military families, and qualifying dependents or survivors of veterans within the programs prosecutors say were affected.
These programs cover medically necessary products under distinct administrative frameworks, yet the indictment alleges that claims induced through illegal kickbacks were ineligible for payment and that inaccurate acquisition-price representations further corrupted reimbursement.
Skin substitutes can deliver legitimate clinical benefits for qualifying chronic wounds, and neither high reimbursement nor use of an advanced allograft proves wrongdoing when practitioners document necessity, wound measurements, prior treatment, product application, wastage, response, and follow-up appropriately.
The case instead focuses upon whether financial arrangements operated through Protectus improperly influenced product selection and whether the companies helped transmit misleading claim information, questions that remain separate from whether an individual patient received some medically valuable treatment.
That distinction will matter when the parties address loss, because prosecutors may contend kickback-tainted claims were categorically ineligible, while the defense may seek credit for delivered products, legitimate care, independent medical judgment, and payments unaffected by any proven misrepresentation.
Nine Counts Focus on Conspiracies and Transactions
Count One charges McMillan with conspiracy to commit healthcare fraud, alleging an agreement to obtain government-program money through materially false representations and kickback-induced skin-substitute claims rather than charging Protectus LLC as a separate defendant in that count.
Count Two alleges a conspiracy to defraud the United States and pay healthcare kickbacks, focusing upon claimed efforts to impair Medicare administration while offering remuneration to providers and representatives who generated federally reimbursable product orders.
Counts Three through Nine accuse McMillan of engaging in monetary transactions involving more than $10,000 in property allegedly derived from the charged conspiracies, requiring prosecutors to trace each specified payment to qualifying criminal proceeds and prove the necessary knowledge.
The transaction section explicitly refers to McMillan acting individually and doing business under the entities described earlier, reinforcing the government’s theory that corporate accounts and company names served as channels through which alleged proceeds were moved and spent.
Corporate ownership does not eliminate personal criminal exposure when an individual knowingly directs unlawful conduct, but ownership alone also does not establish intent, agreement, material deception, unlawful remuneration, proceeds tracing, or responsibility for every employee action.
Protectus Accounts and the Property Allegations
The indictment identifies a Protectus LLC account as the originating account for specified payments involving a 2023 Lamborghini Urus, Las Vegas real estate, Del Mar property, and a 2023 Cadillac Escalade, although the listed transfers are not necessarily complete purchase prices.
Two additional real-estate transactions allegedly originated from accounts held in McMillan’s name, while a payment exceeding $2.5 million connected to a 1997 Cessna Citation aircraft allegedly came from an Elite Elevated Enterprises LLC account.
Elite Elevated Enterprises is identified in the transaction table but is not included among the six companies collectively defined as Protectus, a distinction that careful reporting should preserve rather than automatically merging every associated entity into one corporate category.
Prosecutors also seek forfeiture of listed properties and a money judgment representing traceable proceeds, while federal authorities reported seizing assets valued at approximately $35 million in McMillan’s case during the broader North Texas enforcement operation.
Pretrial seizure does not establish guilt or permanent forfeiture, and McMillan or qualifying third parties may contest ownership, valuation, tracing, probable cause, commingling, substitute-asset claims, and whether particular property was acquired with legitimate or allegedly criminal revenue.
Corporate records will become especially important when funds entered accounts with multiple revenue streams, because prosecutors must trace specified unlawful proceeds while the defense can challenge assumptions that every Protectus receipt or later expenditure shared the same source.
A Signature Case in the 2026 National Takedown
The McMillan indictment was announced during the Justice Department’s 2026 National Health Care Fraud Takedown, which charged 455 defendants across 56 federal districts in cases collectively alleging more than $6.5 billion in false claims and substantial patient harm.
An NBC 5 Dallas-Fort Worth report on the North Texas cases described thirteen defendants accused across seven prosecutions involving wound-care products, laboratory testing, hospice services, neurological procedures, COVID-19 kits, and durable medical equipment.
The Northern District of Texas attributed more than $365 million in alleged fraudulent billing to its coordinated cases, making the approximately $268 million associated with McMillan and Protectus the district’s largest announced matter by claimed government-program payments.
Federal officials credited the Federal Bureau of Investigation’s Dallas office, the Department of Health and Human Services inspector general, the Defense Criminal Investigative Service, and the Department of Veterans Affairs inspector general with investigating the Protectus allegations.
That multiagency team reflects the alleged payer mix, since investigators examining Medicare, military healthcare, and veterans-related benefits can combine claims analysis, provider interviews, corporate records, banking evidence, and program-specific expertise within one prosecution.
Why Multiple Entities Attract Investigative Attention
Operating several limited liability companies is common and lawful, particularly when businesses separate product lines, consulting functions, employment relationships, intellectual property, geographic operations, liability exposure, accounting responsibilities, or risk management for legitimate commercial reasons.
Investigators become concerned when related entities appear to divide one questionable workflow, obscure beneficial control, move money without clear business justification, submit inconsistent records, or make it difficult to identify which company supplied products and earned particular revenue.
The McMillan indictment does not allege that forming multiple LLCs was independently criminal, but prosecutors will likely use common ownership and coordinated records to show that the Protectus companies functioned as parts of one alleged scheme.
The defense may counter with operating agreements, payroll records, separate books, distinct contracts, legitimate services, tax filings, compliance programs, and testimony demonstrating that each company possessed a lawful purpose misunderstood or compressed by the government’s collective label.
Jurors may therefore need to distinguish organizational complexity from concealment, asking whether multiple names obscured criminal conduct or merely reflected ordinary corporate structuring within a specialized medical distribution and consulting business operating nationwide.
Compliance Lessons for Healthcare Companies
Healthcare businesses using affiliated entities should document why each company exists, what services it performs, which employees act for it, how intercompany payments are calculated, and which party bears inventory, collection, denial, warranty, and regulatory responsibilities.
Contracts and invoices should identify fixed or objectively supported product prices, accurately account for every rebate and adjustment, and avoid formulas that merely divide future government reimbursement while eliminating virtually all downside for an ordering provider.
Billing-support teams should use written, current guidance and defined approval procedures, while preserving the source of acquisition-cost figures and ensuring that distributors never pressure enrolled providers to submit information inconsistent with their actual economic obligations.
Sales compensation requires specialized legal review whenever representatives recruit physicians or other federal-program providers, particularly when commissions vary according to reimbursement value, claim success, product volume, provider collections, or orders paid through taxpayer-funded programs.
Boards and owners should receive consolidated compliance reporting across affiliates, because separating inventory, consulting, billing, and marketing among different entities cannot protect an organization when centralized leadership allegedly understands and directs a noncompliant economic arrangement.
Independent audits should trace a sample transaction from manufacturer invoice through product shipment, clinical use, claim submission, insurer payment, provider invoice, rebate adjustment, distributor receipt, representative commission, and any related intercompany transfer or refund.
Manufacturers and Providers Also Face Exposure
Manufacturers should understand how downstream distributors market highly reimbursed products, because aggressive profit promises, inadequate monitoring, or reimbursement-contingent pricing can draw a brand into an investigation even when the manufacturer is not accused or identified publicly.
The McMillan indictment does not name any manufacturer or product brand, so no supplier should be portrayed as participating in the alleged misconduct merely because Protectus distributed skin substitutes from anywhere in the broader commercial marketplace.
Medical providers remain responsible for independent clinical decisions, accurate documentation, truthful cost disclosures, and careful review of arrangements offering unusually large margins, no upfront expense, denied-claim protection, distributor-controlled billing assistance, and profit assurances.
A promise that a supplier will manage claims does not automatically transfer legal responsibility from an enrolled practice, especially when clinicians know that reported acquisition information differs materially from the amount they ultimately expect to pay.
Providers should preserve clinical notes, product logs, shipping records, contracts, invoices, credits, denial correspondence, claim spreadsheets, payment remittances, and compliance advice, because those records can confirm lawful treatment or expose a reimbursement-driven pattern.
Responding to Corporate Criminal Allegations
A federal indictment naming a company in its factual allegations can cause immediate reputational damage for employees, contractors, providers, manufacturers, landlords, lenders, and counterparties, even when the business itself is not listed as a criminal defendant.
Amicus International Consulting’s crisis public-relations guidance emphasizes organized assessment and disciplined communication, principles that should be applied only through accurate statements coordinated with qualified counsel and never through witness pressure, evidence concealment, retaliation, or obstruction.
Its reputation-rebuilding resources likewise support sustained credibility through verifiable information, an approach that requires organizations to distinguish allegations from adjudicated facts while preserving legitimate reporting, regulatory records, court documents, transparency requirements, and public accountability.
Corporate leaders facing scrutiny should immediately preserve emails, messages, accounting files, claim materials, contracts, and device data, establish lawful communication protocols, identify authorized spokespeople, and avoid speculative statements that could later conflict with documents or sworn testimony.
Reputation management cannot erase a legitimate indictment or replace a legal defense, but careful timelines, documented corrections, consistent explanations, and transparent procedural updates can reduce avoidable misinformation while the adversarial process determines the facts.
The Evidence Questions Ahead
Prosecutors must identify who performed each challenged task, which Protectus entity employed that person, what McMillan knew, how he communicated approval, and whether particular provider benefits or representative payments were intended to induce federally reimbursable orders.
They must also prove that selected claim representations were materially false, connect those representations with the alleged agreement, distinguish fraudulent proceeds from legitimate revenue, and trace the property underlying each financial-transaction count through relevant accounts.
McMillan’s defense can challenge witness credibility, search procedures, billing interpretations, safe-harbor analysis, claim sampling, loss calculations, provider independence, employee authority, expert methodology, venue, forfeiture tracing, and the government’s decision to treat six entities collectively.
Evidence that products were delivered or treatments benefited patients may shape medical-necessity and loss disputes, but it would not necessarily defeat a properly proven kickback or false-claim theory involving the economic conditions under which reimbursement was obtained.
Conversely, unusual margins, rapid growth, multiple companies, or luxury purchases cannot replace element-specific evidence, because lawful businesses may be profitable and organizationally complex without their owners knowingly joining or directing a criminal conspiracy.
Cooperating providers, sales representatives, accountants, billing personnel, or former employees could become significant witnesses, but their accounts will need to be evaluated against contracts, contemporaneous communications, financial incentives, immunity arrangements, plea negotiations, and complete corporate records.
What Happens Next for McMillan and Protectus
The prosecution will move through arraignment, discovery, motion practice, expert analysis, asset litigation, and possible negotiations, with years of electronic communications, claims data, banking records, invoices, product files, and corporate documents potentially requiring extensive review.
Possible disputes may include whether the indictment sufficiently states each offense, whether searches and seizures were lawful, whether reimbursement rules provided fair notice, and whether challenged discounts or commissions fit any statutory exception or regulatory safe harbor.
No publicly available timetable can predict the outcome of a case spanning nearly seven years, three government benefit programs, numerous providers, several states, six Protectus entities, substantial seized property, and specialized wound-care reimbursement questions.
The central corporate allegation nevertheless remains clear: prosecutors say McMillan used Protectus LLC and related entities as the business infrastructure for recruiting providers, supplying products, shaping claims, dividing federal payments, rewarding sales representatives, and directing proceeds.
That allegation now must survive adversarial testing, and the government cannot obtain a conviction merely by showing that McMillan owned the companies, approved profitable transactions, or spent business revenue on expensive property after taxes.
Until a guilty plea or jury verdict establishes otherwise, Michael McMillan remains presumed innocent, Protectus-related accusations remain unresolved, and every disputed invoice, claim, commission, account, and transaction must be evaluated under the governing burden of proof.